KdT
KdT Ventures Launches New Biotech Startup to Develop NGM Bio’s Rare Disease Drug Candidate NGM313
KdT Ventures, NGM Bio, NGM313, Rare Disease, Biotechnology, Drug Development, Phase 2 Trial
KdT Ventures Secures $100M Fourth Fund to Fuel Early-Stage Biotech Startups
KdT Ventures, $100M fund, early-stage startups, biotech, frontier science, life sciences investment